Description

Research was carried out on the orphan disease and related drug space in Sub-Saharan Africa with emphasis on 5 countries, namely, Ghana, Nigeria, Uganda, Kenya and Tanzania. An analysis into the systems, treatment regimes and organisation and company involvement and their interrelations was carried out. Each country's status, with respect to these analyses results, was ascertained. Market dynamics, including challenges, drivers and restraints, were also identified along with potential involvement opportunities.